TY - JOUR T1 - Asymptomatic COVID-19 screening tests to facilitate full-time school attendance: model-based analysis of cost and impact JF - medRxiv DO - 10.1101/2021.05.12.21257131 SP - 2021.05.12.21257131 AU - Alyssa Bilinski AU - Andrea Ciaranello AU - Meagan C. Fitzpatrick AU - John Giardina AU - Maunank Shah AU - Joshua Salomon AU - Emily A. Kendall Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/15/2021.05.12.21257131.abstract N2 - Background In March 2021, the Biden administration allocated $10 billion for COVID-19 diagnostic and screening tests in schools.Objective We address to what extent screening tests reduce the risks of full-time in-person learning and how costs of testing compare to short-term financial costs of reduced in-person educational time, at different levels of community incidence.Design We used an agent-based network model to simulate transmission in elementary and middle school communities.Setting We parameterized school structure based on a US setting. Patients (or participants): Students and faculty/staff.Interventions We assess the value of asymptomatic screening tests for students and faculty/staff 1-2 times per week. We also consider vaccination of teachers and of middle school students.Measurements We project 30-day cumulative incidence of COVID-19, proportion of cases detected, proportion of planned and unplanned days out of school, and cost per COVID-19 case averted in students and staff.Results Accounting for programmatic and childcare costs, 5-day school attendance with weekly screening has a lower cost than hybrid models without screening and achieves similarly low rates of transmission. Compared to a 5-day model with no screening, the cost per infection averted with screening drops as community transmission rises. Cost/infection averted is also lower for middle schools than elementary schools, and in settings with less mitigation.Limitations We include only screening and childcare costs, and there is uncertainty in transmission parameters.Conclusions Schools operating in hybrid models may use screening tests to facilitate 5-day attendance with small transmission risk. In the event of resurgent COVID-19 in the fall due to more transmissible variants or seasonal effects, screening can facilitate safe 5-day in-person education across a wide range of community incidence.Funding Sources The authors were supported by the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02; AB, JAS), the National Institute of Allergy and Infectious Diseases (R37AI058736-16S1; AC, K01AI141576; MCF, and K08127908; EAK), the National Institute on Drug Abuse (3R37DA01561217S1; JAS), and Facebook (unrestricted gift; JG, AB, JAS). The papers’ contents are solely the responsibility of the authors and do not represent the official views of the funders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors were supported by the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02; AB, JAS), the National Institute of Allergy and Infectious Diseases (R37AI058736-16S1; AC, K01AI141576; MCF, and K08127908; EAK), the National Institute on Drug Abuse (3R37DA01561217S1; JAS), and Facebook (unrestricted gift; JG, AB, JAS). The papers' contents are solely the responsibility of the authors and do not represent the official views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A -- simulation modelAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code and replication files are publicly available as an R package on GitHub. https://github.com/abilinski/BackToSchool2 ER -